Atara Biotherapeutics (NASDAQ: ATRA) to cut 29% of employees in restructuring

Rhea-AI Filing Summary

Atara Biotherapeutics, Inc. reported a significant workforce reduction, cutting approximately 29% of its current employees and retaining about 15 employees who are considered essential to its strategic priorities. The reduction in force is expected to be completed by January 2026.

The company expects to recognize about $1.3 million in severance and related benefits tied to this action. Approximately half of these charges relate to salary continuation and wages for the 60-day notice period required under the California Worker Adjustment and Retraining Notification Act. The company notes that it may incur additional charges or cash expenditures related to this workforce reduction, with further details to be provided in its Quarterly Report on Form 10-Q for the period ending September 30, 2025.

Positive

• None.

Negative

• Workforce cut of approximately 29%, retaining only about 15 employees and signaling a substantial downsizing of operations.
• Restructuring costs of about $1.3 million in severance and related benefits, with the possibility of additional charges or cash expenditures.

Insights

Equity analyst - biotech restructuring focus

Atara is implementing a major layoff, incurring $1.3M in severance costs.

Atara Biotherapeutics, Inc. is reducing its workforce by approximately 29%, leaving around 15 employees designated as essential for executing its strategic priorities. This indicates a substantial downsizing of operations, which often reflects a shift in focus or an effort to reduce operating expenses.

The company expects about $1.3 million in severance and related benefit charges, with roughly half tied to salary continuation and the 60-day notice period required under the California Worker Adjustment and Retraining Notification Act. These are near-term cash and accounting impacts associated with the restructuring, while any additional charges are flagged as possible but not quantified in this disclosure.

The reduction in force is expected to be completed by January 2026, providing a time frame over which these changes will be implemented. Additional details are expected in the Form 10-Q for the period ending September 30, 2025, which may describe how remaining resources are aligned with the company’s stated strategic priorities.

8-K Event Classification

Item 2.05 — Costs Associated with Exit or Disposal Activities

1 item

Item 2.05 Costs Associated with Exit or Disposal Activities Financial

The company committed to an exit plan involving layoffs, facility closures, or restructuring charges.

Understanding 8-K Material Events →

false 0001604464 0001604464 2025-10-06 2025-10-06

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 6, 2025

Atara Biotherapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware		001-36548		46-0920988
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)
1280 Rancho Conejo Blvd
Thousand Oaks, California				91320
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (805) 623-4211

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		ATRA		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.05 Costs Associated with Exit or Disposal Activities.

On October 6, 2025, Atara Biotherapeutics, Inc. (the “Company”) announced a reduction in its workforce that will impact approximately 29% of its current employees, retaining approximately 15 employees essential to executing on the Company’s strategic priorities. The Company expects to complete the workforce reduction by January 2026. The Company expects to recognize approximately $1.3 million for severance and related benefits for employees laid off under the reduction in force. Approximately fifty percent of these charges are salary continuation payments and wages for the 60-day notice period in accordance with the California Worker Adjustment and Retraining Notification Act. The Company may also incur other charges or cash expenditures not currently contemplated due to events that may occur as a result of, or associated with, the workforce reduction. Additional details will be provided in the Company’s Quarterly Report on Form 10-Q for the period ending September 30, 2025.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

						ATARA BIOTHERAPEUTICS, INC.
Date: October 6, 2025				By:		/s/ AnhCo Thieu Nguyen
						AnhCo Thieu Nguyen President and Chief Executive Officer (Duly Authorized Officer and Principal Executive Officer)

FAQ

What workforce changes did Atara Biotherapeutics (ATRA) disclose?

Atara Biotherapeutics announced a workforce reduction affecting approximately 29% of its current employees, retaining about 15 employees who are considered essential to its strategic priorities.

How much will Atara Biotherapeutics (ATRA) record in severance and related costs?

Atara Biotherapeutics expects to recognize approximately $1.3 million in severance and related benefits associated with the workforce reduction.

When will Atara Biotherapeutics complete its workforce reduction?

Atara Biotherapeutics expects to complete the workforce reduction by January 2026.

How does the California WARN Act affect Atara Biotherapeutics’ restructuring costs?

Approximately 50% of the expected $1.3 million charge relates to salary continuation payments and wages for the 60-day notice period required under the California Worker Adjustment and Retraining Notification Act.

Could Atara Biotherapeutics (ATRA) incur additional restructuring charges?

Yes. The company states it may incur other charges or cash expenditures not currently contemplated as a result of, or associated with, the workforce reduction.

Where will investors find more details on Atara Biotherapeutics’ layoffs?

The company plans to provide additional details about the workforce reduction in its Quarterly Report on Form 10-Q for the period ending September 30, 2025.